MX2023002851A - Tratamiento de la enfermedad de parkinson. - Google Patents

Tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2023002851A
MX2023002851A MX2023002851A MX2023002851A MX2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A
Authority
MX
Mexico
Prior art keywords
disease
parkinson
treatment
prasinezumab
treating
Prior art date
Application number
MX2023002851A
Other languages
English (en)
Inventor
Wagner Zago
Gennaro Pagano
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2023002851A publication Critical patent/MX2023002851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona un método para tratar, prevenir o mejorar la enfermedad de Parkinson con Prasinezumab.
MX2023002851A 2020-09-10 2021-09-10 Tratamiento de la enfermedad de parkinson. MX2023002851A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063076916P 2020-09-10 2020-09-10
US202063076915P 2020-09-10 2020-09-10
US202063076913P 2020-09-10 2020-09-10
US202163158191P 2021-03-08 2021-03-08
PCT/US2021/049785 WO2022056209A1 (en) 2020-09-10 2021-09-10 Treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2023002851A true MX2023002851A (es) 2023-03-22

Family

ID=80629905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002851A MX2023002851A (es) 2020-09-10 2021-09-10 Tratamiento de la enfermedad de parkinson.

Country Status (10)

Country Link
US (1) US20220098291A1 (es)
EP (1) EP4211162A1 (es)
JP (1) JP2023541048A (es)
KR (1) KR20230086674A (es)
AU (1) AU2021338781A1 (es)
CR (1) CR20230121A (es)
IL (1) IL301039A (es)
MX (1) MX2023002851A (es)
TW (1) TW202227131A (es)
WO (1) WO2022056209A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона

Also Published As

Publication number Publication date
AU2021338781A1 (en) 2023-03-30
IL301039A (en) 2023-05-01
CR20230121A (es) 2023-07-26
KR20230086674A (ko) 2023-06-15
US20220098291A1 (en) 2022-03-31
EP4211162A1 (en) 2023-07-19
WO2022056209A1 (en) 2022-03-17
TW202227131A (zh) 2022-07-16
JP2023541048A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
MX2021010701A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedad.
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
MX2021011488A (es) Compuestos y usos de estos.
MY199129A (en) Cancer treatments
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
JOP20200291A1 (ar) معدلات التعبير عن apol1
PH12019502174A1 (en) Modulators of pcsk9 expression
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2020009942A (es) Compuestos y usos de los mismos.
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2021008903A (es) Compuestos y usos de los mismos.
MX2023002851A (es) Tratamiento de la enfermedad de parkinson.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
ZA202110052B (en) Rebamipide for use in prevention and / or treatment of synucleinopathies
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.
WO2020097442A3 (en) Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
WO2020185651A3 (en) Compositions and methods for treating huntington's disease
JOP20210217A1 (ar) طرق لعلاج ألم سطح عين
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2019002629A (es) Formas cristalinas de compuestos terapéuticos y usos de los mismos.